KR102638104B1 - 이특이적 her2 및 cd3 결합 분자 - Google Patents

이특이적 her2 및 cd3 결합 분자 Download PDF

Info

Publication number
KR102638104B1
KR102638104B1 KR1020177004024A KR20177004024A KR102638104B1 KR 102638104 B1 KR102638104 B1 KR 102638104B1 KR 1020177004024 A KR1020177004024 A KR 1020177004024A KR 20177004024 A KR20177004024 A KR 20177004024A KR 102638104 B1 KR102638104 B1 KR 102638104B1
Authority
KR
South Korea
Prior art keywords
her2
seq
delete delete
bispecific binding
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177004024A
Other languages
English (en)
Korean (ko)
Other versions
KR20170038835A (ko
Inventor
나이-콩 브이. 쳉
안드레스 로페즈-알바이테로
홍 쉬
Original Assignee
메모리얼 슬로안 케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안 케터링 캔서 센터 filed Critical 메모리얼 슬로안 케터링 캔서 센터
Publication of KR20170038835A publication Critical patent/KR20170038835A/ko
Application granted granted Critical
Publication of KR102638104B1 publication Critical patent/KR102638104B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020177004024A 2014-07-25 2015-07-24 이특이적 her2 및 cd3 결합 분자 Active KR102638104B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029342P 2014-07-25 2014-07-25
US62/029,342 2014-07-25
PCT/US2015/041989 WO2016014942A1 (en) 2014-07-25 2015-07-24 Bispecific her2 and cd3 binding molecules

Publications (2)

Publication Number Publication Date
KR20170038835A KR20170038835A (ko) 2017-04-07
KR102638104B1 true KR102638104B1 (ko) 2024-02-20

Family

ID=53836217

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177004024A Active KR102638104B1 (ko) 2014-07-25 2015-07-24 이특이적 her2 및 cd3 결합 분자

Country Status (15)

Country Link
US (3) US10519248B2 (enExample)
EP (1) EP3172236B1 (enExample)
JP (1) JP6871155B2 (enExample)
KR (1) KR102638104B1 (enExample)
CN (1) CN107124884B (enExample)
AU (1) AU2015292374B2 (enExample)
BR (1) BR112017001513A2 (enExample)
CA (1) CA2956014C (enExample)
ES (1) ES2832704T3 (enExample)
IL (1) IL250249B (enExample)
MX (1) MX386342B (enExample)
RU (1) RU2017105849A (enExample)
SG (1) SG11201700506TA (enExample)
WO (1) WO2016014942A1 (enExample)
ZA (1) ZA201701341B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102225489B1 (ko) 2013-12-17 2021-03-10 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
JP6871155B2 (ja) 2014-07-25 2021-05-12 メモリアル スローン ケタリング キャンサー センター 二重特異性ｈｅｒ２及びｃｄ３結合分子
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
US11466094B2 (en) 2016-11-15 2022-10-11 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CA3051484A1 (en) * 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
BR112019021182A2 (pt) 2017-04-24 2020-06-02 Memorial Sloan Kettering Cancer Center Agentes de anticorpo anti-cd33
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
CN118772287A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
US20210017295A1 (en) * 2018-03-12 2021-01-21 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
KR20200135935A (ko) * 2018-03-27 2020-12-04 시스트이뮨, 인코포레이티드 유도 및 네비게이션 제어 단백질 및 이의 제조 및 사용 방법
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
WO2019197600A1 (en) * 2018-04-13 2019-10-17 F. Hoffmann-La Roche Ag Her2-targeting antigen binding molecules comprising 4-1bbl
KR20210009421A (ko) * 2018-06-14 2021-01-26 바이오아트라, 엘엘씨 다중 특이적 항체 구조체
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
CA3121168A1 (en) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
EP3894601A4 (en) * 2018-12-11 2023-01-11 The Translational Genomics Research Institute IDENTIFICATION OF HER2 MUTATIONS IN LUNG CANCER AND METHODS OF TREATMENT
CN114502584B (zh) * 2019-02-22 2025-01-10 纪念斯隆凯特琳癌症中心 Cd33抗体和使用所述抗体治疗癌症的方法
AU2020270888A1 (en) * 2019-04-08 2021-11-04 Memorial Sloan Kettering Cancer Center CD19 antibodies and methods of using the same
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
CA3139111A1 (en) * 2019-05-23 2020-11-26 VelosBio Inc. Anti-ror1/anti-cd3 bispecific binding molecules
WO2020264211A1 (en) * 2019-06-26 2020-12-30 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
PE20221511A1 (es) 2019-12-13 2022-10-04 Genentech Inc Anticuerpos anti-ly6g6d y metodos de uso
IL296566A (en) * 2020-03-23 2022-11-01 Cytoarm Co Ltd Bi-specific antibodies for use in producing armed immune cells
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US20230270857A1 (en) * 2020-07-28 2023-08-31 Memorial Sloan Kettering Cancer Center Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
US20230374150A1 (en) * 2020-10-12 2023-11-23 Memorial Sloan Kettering Cancer Center Anti-psma antibodies and uses thereof
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
IL302400A (en) 2020-11-04 2023-06-01 Genentech Inc Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
CA3196191A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
WO2022241235A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN117980888A (zh) * 2021-08-04 2024-05-03 阿布普罗公司 抗her2抗体及其用途
US20240415888A1 (en) * 2021-10-20 2024-12-19 Memorial Sloan Kettering Cancer Center Anti-tshr multi-specific antibodies and uses thereof
KR102857671B1 (ko) 2021-12-29 2025-09-10 건국대학교 글로컬산학협력단 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
KR102803655B1 (ko) 2021-12-29 2025-05-08 건국대학교 글로컬산학협력단 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
AU2024214000A1 (en) * 2023-02-04 2025-08-21 Imagion Biosystems, Inc. Method to assess nodal disease using iron oxide nanoparticles in magnetic resonance imaging
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof
WO2025085781A1 (en) 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
US20140170149A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
ES2589769T3 (es) 2009-02-27 2016-11-16 Massachusetts Institute Of Technology Proteínas modificadas con alta afinidad por quelatos de DOTA
KR101834026B1 (ko) * 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 항-ｇｄ2 항체
SMT201900500T1 (it) * 2011-05-08 2019-11-13 Legochem Biosciences Inc Coniugati di agente protettivo-proteina e metodo per preparare i medesimi
ES2758884T3 (es) * 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
IN2014CN04039A (enExample) * 2011-11-02 2015-10-23 Ajinomoto Kk
WO2013188693A1 (en) * 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
CN112079929A (zh) * 2012-11-21 2020-12-15 武汉友芝友生物制药有限公司 双特异性抗体
DK3406633T3 (da) * 2013-07-25 2022-03-28 Cytomx Therapeutics Inc Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
NZ760065A (en) 2013-12-17 2022-12-23 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
JP6871155B2 (ja) 2014-07-25 2021-05-12 メモリアル スローン ケタリング キャンサー センター 二重特異性ｈｅｒ２及びｃｄ３結合分子
WO2016130539A2 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CA3051484A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
US20140170149A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3

Also Published As

Publication number Publication date
JP6871155B2 (ja) 2021-05-12
NZ729286A (en) 2023-12-22
CN107124884B (zh) 2022-11-01
US20200199248A1 (en) 2020-06-25
MX2017001031A (es) 2017-05-04
US20260071005A1 (en) 2026-03-12
WO2016014942A1 (en) 2016-01-28
AU2015292374A1 (en) 2017-03-16
US11987642B2 (en) 2024-05-21
CA2956014C (en) 2023-10-31
EP3172236B1 (en) 2020-09-30
CN107124884A (zh) 2017-09-01
SG11201700506TA (en) 2017-02-27
ZA201701341B (en) 2021-05-26
EP3172236A1 (en) 2017-05-31
KR20170038835A (ko) 2017-04-07
IL250249A0 (en) 2017-03-30
BR112017001513A2 (pt) 2018-02-14
JP2017527274A (ja) 2017-09-21
MX386342B (es) 2025-03-18
ES2832704T3 (es) 2021-06-11
CA2956014A1 (en) 2016-01-28
RU2017105849A (ru) 2018-08-29
US10519248B2 (en) 2019-12-31
IL250249B (en) 2021-04-29
AU2015292374B2 (en) 2020-09-03
US20170210819A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
KR102638104B1 (ko) 이특이적 her2 및 cd3 결합 분자
JP7203446B2 (ja) Ｔｉｇｉｔ結合物質およびその使用法
US20250179169A1 (en) Combination therapy for treatment of disease
US20260062501A1 (en) Bispecific her2 and cd3 binding molecules
US20210324079A1 (en) Bispecific her2 and cd3 binding molecules
US20250353915A1 (en) Antibodies to galectin-3 and methods of use thereof
KR20180081606A (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
PT2486941T (pt) Anticorpos humanos que ligam a cxcr4 e utilizações dos mesmos
TW200823237A (en) Antibodies to NTB-A
EP3574012A1 (en) Bispecific her2 and cd3 binding molecules
HK1238654B (en) Bispecific her2 and cd3 binding molecules
HK1238654A1 (en) Bispecific her2 and cd3 binding molecules

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170214

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200724

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220928

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230523

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231120

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240214

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240215

End annual number: 3

Start annual number: 1

PG1601 Publication of registration